NCCN Research & Business Resources
NCCN Oncology Insights Report on Non-Small Cell Lung Cancer 1.2010
The National Comprehensive Cancer Network® (NCCN®) is pleased to introduce
a new analytic and evaluative information product, NCCN Oncology Insights
Reports™. Herein, we present the first in the series,
The NCCN Oncology Insights Report on Non-Small Cell Lung Cancer (NSCLC).
This and subsequent NCCN Reports are intended to communicate to interested constituencies
in the cancer community the views of thought leaders on the types and quanta of
data and the study design or analysis deemed cogent and persuasive in making recommendations
about appropriate treatments across the spectrum of decision-making processes.
NCCN Reports address issues along the continuum of care as decisions
and recommendations are made for early stage disease through recurrence and metastasis
into surveillance and then palliation.
The NCCN views the availability of our new information product as yet another step
in ongoing collaborations that foster innovation and acceptance of improved health
care technologies. We believe that NCCN Reports will expand
the dialogue and thus, better meet the needs of patients whom we serve.
Below we've provided you with some frequently asked questions about NCCN Reports
to inform your decision to invest in this offering:
Who should be interested in the NCCN Report on NSCLC?
The audience for the NCCN Reports is any organization with an interest and investment
in timely and relevant insights into cancer care.
What will the NCCN Report on NSCLC provide to me and/or my organization?
The NCCN Report on NSCLC will provide unique expert insight into areas such as clinical
trial design, current and future trends in treatment, and the importance of biomarkers
by placing unparalleled access to expert judgment at your fingertips. For additional
value, subscribers will receive updates if important issues arise within the 12
month period after the Report is obtained. Further, subscribers will have the option
to pose customized questions to the NCCN to enhance their use of the Report.
For more details, please see the Overview of NCCN Oncology Insights Reports on the
How can I or someone within my organization purchase the NCCN Report on NSCLC?
NCCN has partnered with Oncology Reimbursement Management to distribute this offering.
Ron Schleif, Oncology Reimbursement Management
11550 North Meridian Suite 101
Carmel, IN 46032
Overview of NCCN Oncology Insights Reports
Because of the many advances in cancer research (molecular biology, genetics, biologics,
etc.), the understanding of the complexity underlying the diseases of cancer has
grown exponentially over the past decade. In parallel, advances in diagnostics and
treatments for NSCLC have led to better outcomes and higher standards of what outcomes
These new understandings and treatments have raised multiple new questions and issues
with regard to the decisions on the appropriate treatment of NSCLC patients. Among
the areas to be explored in the report:
- Biomarkers are increasingly recognized and applied for guidance in diagnosis, prognosis
and treatment decisions and evaluation.
- Biologics and newer cancer treatments are enabling the possibility for new combined
treatment modalities in earlier stage disease
- Maintenance therapy has been shown to be useful, but optimal therapy choices before
and after maintenance therapy need clarification
- The importance of performance status on treatment decisions
- Comparative effectiveness is becoming an expectation across all treatments and diseases,
and will prove difficult to accomplish within the complexity of cancer diseases
Unique features of the NCCN Report
- The authoritative report that evaluates and characterizes the considerations, parameters
and issues that are critical in deciding appropriate future NSCLC treatments, enabling
organizations to incorporate these valuable insights into their clinical development
plans and business decisions, as necessary
- The authoritative report identifying the decision parameters and standards by which
products and diagnostics are incorporated into appropriate cancer management recommendations
- Assessment of recently reported clinical results, and how the available information
aligns with the aforementioned decision parameters and standards
- Listing and discussion of ongoing research trials that could affect accepted cancer
treatments in the future (study, schema, approximate date results will be available)
- The authoritative report discussing the approach, process and thinking behind appropriate
Key Learnings and Benefits
Insights to issues, data and information that will drive clinical development and
discussion now and over the next 3 to 5 years on how decision-making
regarding the appropriate diagnosis and treatment of NSCLC will change.
- What we know today about these clinically relevant issues, and what will be critical
to business decisions moving forward
- The rationale and data/information behind recent changes to NSCLC diagnostic and
- Which ongoing/planned NSCLC clinical study results could change diagnostic and therapeutic
- How will biomarkers likely will change the landscape of NSCLC management
NSCLC Thought Leaders
NCCN has brought together a team of NSCLC experts to provide insights on the evaluation
and incorporation of diagnostics and therapeutics into recommendations for appropriate
use in NSCLC patients.
David Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wallace Akerley, MD
Huntsman Cancer Institute at the University of Utah
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute
George Simon, MD
Fox Chase Cancer Center
Purchase Prior to November 15, 2010 - $85,000
Purchase After November 15, 2010 - $100,000
Restrictions and Limitations:
NCCN Reports are solely for internal organization use. Prior
to receiving the report, all parties must sign an End User Agreement.